Newlink's general IDO pathway inhibitor Indoximod looking at least as good as Incyte's IDO inhibitor in advanced melanoma. Good news for melanoma patients. Market appreciating NLNK undervalue with stock up over 25% today. See our Seeking Alpha article from last week HERE.
Sign up to follow us on SeekingAlpha for access to future reports. Our model, hypothetical portfolio is up over 30% for the year. See our current results on our Amp Bio Research web site. Check out our LinkedIn Amp PAGE to become one of our first LinkedIn followers to assure you hear about our future reports and results.
Past performance does not predict future performance. You should do your own diligence before making any stock trades. This post is NOT investment advice.